Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Purple Biotech Ltd. (PPBT.TA)
Rehovot, IL
Purple Biotech Ltd., a clinical-stage company, is focused on creating therapies for cancer patients in the United States, specifically addressing challenges like tumor immune evasion and drug resistance. Its diverse oncology pipeline includes CM24, a humanized monoclonal antibody that targets and blocks carcinoembryonic antigen related cell adhesion molecule 1 (CEACAM1). Currently in Phase 2 clinical trials, CM24 is being investigated as a combination therapy with anti-PD-1 checkpoint inhibitors for treating pancreatic ductal adenocarcinoma. Another candidate is NT219, a small molecule compound in Phase 1/2 clinical trials, which functions by inhibiting insulin receptor substrate 1 and 2 (IRS1/2) and signal transducer and activator of transcription (STAT). This compound is being developed for recurrent and/or metastatic squamous cell carcinoma of the head and neck, or colorectal adenocarcinoma. Furthermore, IM1240, a multi-valent antibody designed to activate an anti-tumoral immune response against 5T4-positive tumors, is in its preclinical stage. The company has established significant collaborations, including an agreement with Bristol Myers Squibb Company for Phase 2 clinical trials to assess CM24 in combination with the PD-1 inhibitor nivolumab and chemotherapy, as well as a partnership with Mor Research Applications. Formerly known as Kitov Pharma Ltd., the company adopted the name Purple Biotech Ltd. in December 2020 and is headquartered in Rehovot, Israel.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | -16.67% | -16.67% | -77.27% | -98.48% | -99.42% | -99.94% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-34.8% Q1'26: +100.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-9,032.4% Q1'26: -259.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+85.7% Q1'26: +250.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q1'26: -0.02× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 | Dec 2027 | Dec 2028 |
|---|---|---|---|---|---|
| Revenue |
—
|
—
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBITDA |
-7.05M
|
-29.72M
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-7.24M
|
-29.72M
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-7.24M
|
-28.79M
|
—
— – —
|
—
— – —
|
—
— – —
|
| SGA |
2.94M
|
3.51M
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-0.02
|
-0.03
|
—
— – —
|
—
— – —
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-25 | B | 3/5 | 5/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-20 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-19 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-18 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-12 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-11 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-29 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-28 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gil Efron | CEO & Director | 524.0K | male |
| Michael Schickler | Head of Clinical & Regulatory Affairs | 298.0K | — |
| Shai Lankry | Chief Financial Officer | 120.0K | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PPBT.TA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
